On October 9, GRAIL, Inc. rose 5.56% in regular trading, trading at $139.57 per share, with turnover of $7.125 million. The move extends a multi-day rally driven by continued positive market reaction to the FDA's Molecular and Clinical Genetics Devices Panel vote on the Galleri multi-cancer early detection test.

The advisory committee voted unanimously 10-0 on safety, 6-4 on efficacy, and 7-2 with one abstention on benefit-risk for detecting multiple cancers in adults aged 50 or older. Supporting data from the PATHFINDER 2 study showed that adding Galleri to recommended screenings increased cancer detection 6.5-fold, with 71% of newly identified cancers detected at stages I to III. While the panel's recommendation is non-binding and final FDA approval remains pending, market sentiment has turned clearly optimistic. UBS has maintained a Buy rating and raised its price target to $175 from $105.

GRAIL, Inc. is a healthcare company pioneering next-generation sequencing-based technologies for early cancer detection, with its platform capable of detecting over 50 cancer types from a single blood draw.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)